RTW Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

RTW Investments’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,106,341	Closed	-$5.67M	–	79
2022 Q4	$5.67M	Hold	5,106,341	–	–	0.12%	56
2022 Q3	$11.9M	Buy	5,106,341 +747,908	+17%	+$2.65M	0.28%	48
2022 Q2	$13.2M	Sell	4,358,433 -321,979	-7%	-$1.57M	0.34%	51
2022 Q1	$31.8M	Buy	4,680,412 +1,817,214	+63%	+$13M	0.66%	42
2021 Q4	$23.9M	Buy	2,863,198 +1,466,995	+105%	+$12.1M	0.35%	63
2021 Q3	$10.4M	Buy	+1,396,203	New	+$8.65M	0.16%	77

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

RTW Investments's JNCE Position: Q1 2023 in Review

RTW Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 5,106,341 shares — an estimated $5.67M sold.

RTW Investments first reported a position in JNCE in Q3 2021 and held it in 6 quarters. The position peaked at $31.8M in Q1 2022. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

RTW Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
RTW Investments sold 5,106,341 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $5.67M.
RTW Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
RTW Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $31.8M in Q1 2022.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on RTW Investments's 13F filing for Q1 2023, filed 15 May 2023.